Roche: divarasib superior in Phase III Krascendo1 vs approved KRAS G12C inhibitors
Key highlights
- Roche reported divarasib showed superiority in a head-to-head global Phase III Krascendo1 trial against approved KRAS G12C inhibitors.
- The trial evaluated divarasib in previously treated patients with KRAS G12C-positive non-small cell lung cancer.
- Roche said detailed data from Krascendo1 will be presented at an upcoming medical meeting.
- Chugai Pharmaceutical issued a notice referencing Roche’s media release and linked to the announcement.
Trial outcome
Roche issued a media release reporting that the global Phase III Krascendo1 trial found the KRAS G12C inhibitor divarasib to be superior in a head-to-head comparison with approved KRAS G12C inhibitors in previously treated non-small cell lung cancer patients with the KRAS G12C mutation.
Next steps
Roche said detailed data from the Krascendo1 study will be presented at an upcoming medical meeting.
Corporate notice
Chugai Pharmaceutical published a notice referencing Roche’s media release and provided a link to the Roche announcement.
Source: Chugai Pharmaceutical
